Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

Diphtheria Toxin CRM197 mutant from Corynebacterium diphtheriae

  • Photo non disponible
Cat No: 23218
Proteins - More Proteins
Cayman

Diphtheria toxin CRM197 mutant from C. diphtheriae is an inactive and non-toxic version of diphtheria toxin (Item No. 19657). It contains a single base change in the structural gene resulting in the substitution of glutamic acid for glycine which bloc...

More
: 250 µg

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Correlated keywords:
  • CRM-197 nontoxic
Product Overview:
Diphtheria toxin CRM197 mutant from C. diphtheriae is an inactive and non-toxic version of diphtheria toxin (Item No. 19657). It contains a single base change in the structural gene resulting in the substitution of glutamic acid for glycine which blocks ADP-ribosylation.{38537} Diphtheria toxin CRM197 mutant has no enzymatic activity but is immunologically indistinguishable from diphtheria toxin. Formulations containing diphtheria toxin CRM197 mutant have been used as carriers of conjugated polysaccharides in the development of vaccines against encapsulated bacterial pathogens.{38538}
Size 250 µg
Shipping wet ice
Formulation Each vial, when reconstituted to 0.25 ml with water, contains 250 µg of diphtheria toxin CRM197 mutant in 0.01 M sodium phosphate with 5% lactose at pH 7.4
Purity ≥90% (estimated by SDS-PAGE)
Custom Code 3504.00
UNSPSC code 12352204

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : Diphtheria Toxin CRM<sub>197</sub> mutant from <em>Corynebacterium diphtheriae</em> There are 10 products.

Search